Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lirentelimab in Adult Subjects With H-1 Antihistamine Refractory Chronic Spontaneous Urticaria

NCT05528861 is registered in ClinicalTrials.gov with Allakos Inc. as lead sponsor.

NCT NCT05528861
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05528861 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lirentelimab in Adult Subjects With H-1 Antihistamine Refractory Chronic Spontaneous Urticaria
Lead sponsor
Allakos Inc.
Phase
Phase 2
Overall status
Terminated
Start date
October 26, 2022
Completion date
April 18, 2024
Enrollment
127 (actual)
Sites
67

Conditions

As the registry lists them; a condition with its own page is linked.

chronic spontaneous urticaria